TrialCancer research communications2023

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.

Myrto Moutafi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.